In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s greatest advancements in using artificial intelligence from the previous year.
In a recent video interview with Applied Clinical Trials, Dipanwita Das, CEO & co-founder at Sorcero, discussed advancements and future trends in clinical trials. Key challenges include high costs, long timelines, lack of diversity, and rigid protocols. Das highlighted technological advancements such as AI, real-time monitoring, and historical data analysis, which are all expected to optimize trial design and patient recruitment in 2025 and beyond.
ACT: Looking back at 2024, what advancements in clinical technology are you most proud of the industry for achieving?
Das: Well, I think a lot of advancements and progress has been made in the patient matching and recruitment. We've successfully seen industry use AI (artificial intelligence) to analyze electronic health records to more effectively identify eligible trial participants and I think that's really important. Also, finding the right participants before you're able to target them. That's the other point that's been really difficult to do, is that personalization and the targeting. Real-time data monitoring saw a lot of progress as well in using AI to stay abreast in real time, instead of being able to circumvent potential hurdles and issues as they show up, rather than six, eight, 10 months after the effect, which would add absolutely years to the length of a trial and the complexity thereof, and also make it more expensive. We've seen a lot of progress in design optimization, where you're actually using more historical trial data to reflect on how future trials of similar compounds or similar therapies can be optimized and of course, the dream of decentralized trials, diversity needs a lot of work to actually be instrumented and implemented and I think investment in more decentralization and hybrid trials, we've seen some great progress in that as well in the course of 2024.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.